Clonz Biotech Pvt Ltd

CLONZ is a biopharmaceutical firm promoted by a group of young and passionate Biotechnologists, focused on the development, manufacturing and commercialization of Human Therapeutic biosimilar Monoclonal Antibodies (MAbs). Clonz got incorporated in 2009 and started its operations in September 2010 at Genome Valley, Hyderabad, India With experienced team coming from recognized leaders in recombinant biosimilar manufacturing, Clonz is committed to delivering quality biologics to make treatment and care affordable to the world population in many disease indications, with special emphasis on Oncology. DSIR (Govt.of India) Recognised R&D unit with fully integrated Mammalian platform to Develop Biosimilar MAbs We are happy to announce that Sri Krishna Pharmaceuticals Ltd has recently acquired 100% equity in CLONZ Biotech Pvt Ltd. Under this new leadership, we are making substantial investments in expanding our capabilities, viz the state-of-the-art Drug Substance and Drug Product manufacturing facilities for CDMO.